One-year rotational stability and refractive outcomes of the Acriva BB T UDM 611 toric ıntraocular lens: A prospective study

To evaluate the 1-year clinical outcomes of the Acriva BB T UDM 611 toric intraocular lens (IOL) following cataract surgery in patients with preoperative corneal astigmatism, focusing on rotational stability, refractive efficacy, visual acuity, contrast sensitivity (CS), and safety.

This prospective longitudinal study included 39 eyes of 32 patients with age-related cataract and regular corneal astigmatism ≥1.0 diopter who underwent phacoemulsification and toric IOL implantation at a tertiary eye care center. Preoperative and postoperative assessments included uncorrected (UDVA) and corrected distance visual acuity (CDVA), corneal and refractive astigmatism, IOL rotation, decentration, and tilt. The CSV-1000 test was used to measure CS at 2.5 m under photopic, mesopic, and mesopic with glare conditions. Adverse events were recorded.

The mean logMAR UDVA improved significantly from 0.95± 0.39 preoperatively to 0.06 ± 0.10 at 1 year (p < 0.001). The refractive cylinder decreased from -2.17 ± 1.75 D to -0.21 ± 0.32 D (p < 0.001). The mean IOL rotation was 1.61° ±2.35°, with 89.7% of eyes within ±5° and all within ±10° of the intended axis. No IOL repositioning was required. No patients reported disturbing visual phenomena, and no vision-threatening complications occurred during the follow-up.

The Acriva BB T UDM 611 toric IOL demonstrated excellent rotational stability, significant refractive accuracy, and favorable safety and CS outcomes at 1 year postoperatively. These results support its efficacy in correcting pre-existing corneal astigmatism in cataract patients.